Skip to search formSkip to main contentSkip to account menu

MNRP1685A

Known as: Anti-Neuropilin-1 Monoclonal Antibody MNRP1685A 
A human IgG1 monoclonal antibody directed against neuropilin-1 (NRP1), with potential antiangiogenic and antineoplastic activities. Upon intravenous… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Rhodocetin-αβ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models
The tumor vasculature differs from normal blood vessels in morphology, composition and stability. Here, we describe a novel tumor… 
2012
2012
Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans
To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats… 
2011
2011
A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors.
3050^ Background: Neuropilin-1 (NRP1) is involved in remodeling and maturation of blood vessels. MNRP1685A is a human monoclonal… 
2011
2011
Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)-treated phase I patients.
e13598 Background: Neuropilin-1 (NRP1), a high affinity receptor for members of the VEGF family, is expressed on endothelial… 
2010
2010
A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.
3014 Background: Anti-NRP1 specifically targets neuropilin-1 (NRP1), a multi-domain receptor known to bind a variety of ligands… 
2010
2010
A phase Ib study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with…
TPS180 Background: This study seeks to determine whether the anti-angiogenic antibody anti-NRP1 can be safely combined with the… 
2010
2010
372 A phase I dose-escalation study of the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously to patients with advanced solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)